OKYO Pharma Will Present Clinical Trial Plans
The biopharmaceutical firm will outline its upcoming global Phase 3 study for corneal pain treatments.
Updated on Sept. 29, 2026 in Biotech
Live Poll
Do you trust that pharmaceutical companies prioritize patient needs when engaging with medical experts?
OKYO Pharma announced that its leadership will discuss development plans for neuropathic corneal pain therapies at industry conferences this October. These sessions will detail the company's research trajectory ahead of a projected Phase 3 trial launch in the second half of 2026.
Why it matters
The company aims to engage ophthalmologists and optometrists to address current gaps in treating anterior segment eye diseases. These discussions are part of a broader strategy to align clinical development with real-world practitioner needs.
The firm is preparing to initiate a global Phase 3 pivotal clinical trial scheduled for the second half of 2026, which is expected to enroll 111 patients.
The players
OKYO Pharma
A clinical-stage biopharmaceutical company focused on developing novel therapies for neuropathic corneal pain and anterior segment eye diseases.
Robert J. Dempsey
The Chief Executive Officer of OKYO Pharma who is directing the company's clinical and commercial strategy.
The details
OKYO Pharma focuses on developing therapies for neuropathic corneal pain and anterior segment eye diseases, which affect the front structures of the eye including the cornea. The company plans to utilize upcoming industry conferences to share clinical frameworks with eye-care professionals who manage these conditions. This outreach is intended to incorporate clinical feedback into the design of their upcoming trial protocols.
Timeline
September 30 - October 1, 2026: American Academy of Optometry conference in Anaheim.
October 8, 2026: Presentation at Eyecelerator in New Orleans at 1:29 PM CT.
October 9-12, 2026: American Academy of Ophthalmology conference in New Orleans.
Second half of 2026: Planned start of the global Phase 3 clinical trial.
The Tech Race
The company is positioning its pipeline within the competitive landscape of clinical-stage ophthalmic therapeutics. It is now moving toward a pivotal study, aligning its research trajectory with established clinical development benchmarks for eye disease treatments.
This development serves as a milestone for practitioners who manage patients with chronic corneal pain, as the trial progresses toward potential future therapeutic options. Availability and specific treatment timelines for these patients will be determined by the results of the 2026 study.
The takeaway
The upcoming presentations in Anaheim and New Orleans serve as a precursor to the company's scheduled 2026 trial launch. Investors and clinicians should monitor the company's official communications during these conferences for specific trial design details.
What happens next
The company will begin its global Phase 3 clinical trial in the second half of 2026, contingent on final preparations.
Further reading
For broader trends in drug development, visit Biotech.
More information
View OKYO Pharma corporate information to track future clinical updates.
Live Poll
Do you trust that pharmaceutical companies prioritize patient needs when engaging with medical experts?
